Other Consolidated Financial Statement Detail (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Long-term taxes payable	$ 198,500,000		$ 198,500,000
Other Income (Expense), Net
Interest income	2,400,000	900,000	5,100,000	5,200,000
Interest expense	(7,100,000)	(7,300,000)	(14,700,000)	(18,900,000)
Impairment of investments	0	(1,400,000)	0	(1,700,000)
Gain (loss) on sales of investments, net	13,600,000	5,700,000	16,600,000	10,100,000
Foreign exchange gains (losses), net	(1,400,000)	(5,300,000)	(4,700,000)	(7,900,000)
Other, net	(2,600,000)	(3,000,000)	(3,000,000)	(11,700,000)
Total other income (expense), net	4,861,000	(10,428,000)	(740,000)	(24,885,000)
Accrued Expenses and Other
Revenue-related rebates	474,500,000		474,500,000		416,300,000
Employee compensation and benefits	274,100,000		274,100,000		343,400,000
Royalties and licensing fees	190,000,000		190,000,000		160,700,000
Current portion of contingent consideration obligations	185,700,000		185,700,000		29,000,000
Deferred revenue	145,000,000		145,000,000		172,700,000
Clinical development expenses	62,500,000		62,500,000		55,200,000
Collaboration expenses	37,700,000		37,700,000		18,700,000
Construction in progress accrual	15,700,000		15,700,000		25,000,000
Other	263,700,000		263,700,000		285,600,000
Total accrued expenses and other	1,495,549,000		1,495,549,000		1,355,187,000
Component of accrued expenses and other
Accrued Expenses and Other
Revenue-related rebates	$ 321,100,000		$ 321,100,000		$ 264,900,000